Absci Corporation (ABSI) vs Lycia Therapeutics Inc. (LYCA)

Absci Corporation ABSI 10.17 +8.31%
Lycia Therapeutics Inc. LYCA 30.50 +5.90%

Absci Corporation and Lycia Therapeutics Inc. are both Biotechnology companies. Absci Corporation and Lycia Therapeutics Inc. are of similar size ($1.7B and $1.6B).

Metric	ABSI	LYCA	Biotechnology median
P/E	n/m	—	10.60
P/S	1,024.93	—	9.40
P/B	6.50	—	2.13
Price to free cash flow	n/m	—	25.18
EV/EBITDA	n/m	—	0.66
EV/Sales	896.21	—	9.02
Earnings yield	(7.87%)	—	(32.88%)
Free cash flow yield	(6.80%)	—	(23.13%)

Metric	ABSI	LYCA	Biotechnology median
Gross margin	100.00%	—	68.51%
Operating margin	(8,084.50%)	—	0.00%
Net margin	(7,756.37%)	—	0.00%
Free cash flow margin	(6,969.83%)	—	0.00%
Return on equity	(57.72%)	—	(51.96%)
Return on assets	(50.57%)	—	(46.06%)
Return on invested capital	(174.74%)	—	0.00%

Metric	ABSI	LYCA	Biotechnology median
Revenue growth (TTM)	(62.28%)	—	6.76%
EPS growth (last fiscal year)	10.64%	—	29.88%
Revenue growth, 5-year CAGR	(10.14%)	—	9.75%
Net income growth, 5-year CAGR	0.00%	—	0.00%

Metric	ABSI	LYCA	Biotechnology median
Debt to equity	0.00	—	0.00
Current ratio	10.63	—	4.97
Net debt to EBITDA	1.32	—	1.01

Metric	ABSI	LYCA	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	ABSI	LYCA	Biotechnology median
Market cap	1.61b	1.66b	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack